01542-A: The Effects of Baicalein on Canine Osteosarcoma Cells
Grant Status: Closed
AbstractLAY ABSTRACT: The use of nutraceuticals, particular those classified as flavonoids is growing in veterinary medicine. Many oncologists do not recommend their use based on the hypothesis that these bioactive antioxidants may hinder common chemotherapeutics, although there is little scientific data to support this viewpoint. There is a need to understand the general cell biology and mechanisms that underlie the anti-proliferative effects of the flavones and whether their use is synergistic or diminutive with common chemotherapeutic agents. Using a flavone, such as baicalein, with pharmacologic activity in the low micromolar range will provide insight into the anti-proliferative and potential synergistic actions of this particular flavone. Hopefully the information gained from in-vivo study of baicalein will open the door for pharmacokinetic studies in dogs and xenograft osteosarcoma studies. Additionally this work will be the catalyst for future clinical studies examining baicalein as a potential anti-neoplastic agent that can delay tumor growth in canine osteosarcoma.
None at this time.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.